2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Slide40of 43FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA. Many interesting biomarker studies underway to determine the best biomarkers to predict CVD and other non-AIDS related outcomes in HIV • Studies focused on inflammatory markers as potential targets for atherosclerotic therapies • New lipid lowering agents (PCKS9) and diabetes agents (oral rather than injectable semaglutide) • Impact of treatments to lower HIV-related inflammation on CVD? • Role of newer agents (e.g. integrase inhibitors) and CVD? • Are we seeing smaller increases in CVD risk today than just a few years ago? • Will moving forward thinking about MI type help understand some of the differences between PLWH and uninfected Interesting future directions •

Summary

Slide41of 43FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA. • Not a comprehensive summary of all relevant studies, in particular whole day sessions could be done on imaging studies; inflammation and other biomarkers, etc. • CVD in HIV is an important outcome with substantial morbidity and mortality • Endpoint ascertainment, central adjudication, and identifying MI types is key in defining risk and mechanism in HIV for research • Type 2 MI are a much larger proportion of events than in the general population and almost half of all MIs in PLWH • Traditional CVD risk factors common: focus on traditional risk prevention but additional targets also needed • Focus on ART treatment • Many many questions remain unanswered regarding inflammation and the role and potential intervention targets

Thanks! Manymanycollaborators CNICScollaborators include: MariKitahata DanDrozd ChrisDelaney RobinNance SusanHeckbert MattBudoff MikeSaag MichaelMugavero JamesWillig GreerBurkholder

RichardMoore PriscillaHsue CarlGrunfeld PeterHunt IngaPeter JoeEron WChrisMathews KenMayer DavidTirchwell MattFeinstein

NA-ACCORDcollaborators (many!!!!)

Funding NIAID:P30-AI027757,R24-AI067039, NHLBI:R01HL126538

Thanks toMattFeinstein,DanDrozdandPriscillaHsue,allofwhom providedslidesused inthis talk

Slide42of 42FromHMCrane, MD inNewOrleans, LA, December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.